BOSTON,–(BUSINESS WIRE)–PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the closing of its…
According to filings with the U.S. Securities and Exchange Commission, PepGen is raising $80,100,000.00 in new funding. About PepGen: PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in…
Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, PepGen is raising $112,499,887.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James McArthur played a key…
Boston, MA – According to filings with the U.S. Securities and Exchange Commission, PepGen is raising $51,772,544.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Caroline Godfrey played…